{"id":169214,"date":"2024-05-06T02:42:37","date_gmt":"2024-05-06T06:42:37","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/cellectis-announces-completion-of-the-additional-equity-investment-by-astrazeneca\/"},"modified":"2024-08-18T11:48:11","modified_gmt":"2024-08-18T15:48:11","slug":"cellectis-announces-completion-of-the-additional-equity-investment-by-astrazeneca","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/cellectis-announces-completion-of-the-additional-equity-investment-by-astrazeneca.php","title":{"rendered":"Cellectis Announces Completion of the Additional Equity Investment\u00a0by AstraZeneca"},"content":{"rendered":"<p><![CDATA[NEW YORK, May  06, 2024  (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS \u2013 NASDAQ: CLLS) a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that, following clearance from the French Ministry of Economy and satisfaction of all other closing conditions, AstraZeneca (LSE\/STO\/Nasdaq: AZN) completed the additional equity investment of $140M in Cellectis, as previously announced by Cellectis on November 1 and 15, 2023 (the\u00a0\u201cAdditional Investment\u201d).]]><\/p>\n<p>See original here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/05\/06\/2875525\/0\/en\/Cellectis-Announces-Completion-of-the-Additional-Equity-Investment-by-AstraZeneca.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Cellectis Announces Completion of the Additional Equity Investment\u00a0by AstraZeneca\">Cellectis Announces Completion of the Additional Equity Investment\u00a0by AstraZeneca<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>See original here: Cellectis Announces Completion of the Additional Equity Investment\u00a0by AstraZeneca <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/cellectis-announces-completion-of-the-additional-equity-investment-by-astrazeneca.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-169214","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/169214"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=169214"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/169214\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=169214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=169214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=169214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}